We are live on ! Find out more
NKTR icon

Nektar Therapeutics

158 hedge funds and large institutions have $84.2M invested in Nektar Therapeutics in 2025 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 42 increasing their positions, 47 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

620% more call options, than puts

Call options by funds: $885K | Put options by funds: $123K

88% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 16

9% more funds holding

Funds holding: 145 → 158 (+13)

5.49% less ownership

Funds ownership: 72.04% → 66.55% (-5.5%)

11% less repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 47

36% less capital inflows, than outflows

Capital inflows: $15.4M | Capital outflows: $24.1M

Holders
158
Holders Change
+13
Holders Change %
+8.97%
% of All Funds
2.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
30
Increased
42
Reduced
47
Closed
16
Calls
$885​K
Puts
$123​K
Net Calls
+$762​K
Net Calls Change
+$549​K

NKTR Hedge Fund Activity: Q1 2025 in Review

158 of the 7,493 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q1 2025, worth a combined $84.2M — down 32% from $124M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new NKTR positions and 16 closed out — a net gain of 14 holders — while 42 added to existing stakes and 47 trimmed.

The largest buyer was Almitas Capital, adding an estimated $3.21M. The largest seller was Samlyn Capital, exiting entirely with an estimated $8.99M sold.

  • 158 institutional investors held Nektar Therapeutics (NKTR) as of Q1 2025, up from 145 in Q4 2024.
  • Funds reported $84.2M of Nektar Therapeutics stock for Q1 2025, down 32% quarter-over-quarter.
  • 30 funds opened new Nektar Therapeutics positions in Q1 2025 and 16 closed out, a net change of +14 holders.
  • The largest Nektar Therapeutics buyer in Q1 2025 was Almitas Capital, an estimated $3.21M added.
  • The largest Nektar Therapeutics seller in Q1 2025 was Samlyn Capital, an estimated $8.99M sold.

Based on aggregated 13F filings for Q1 2025.